Results 51 to 60 of about 1,534 (92)
, 2006 Most deaths in beta-thalassemia major result from cardiac complications due to iron overload. Differential effects on myocardial siderosis may exist between different chelators.
Gotsis, ED +11 more
core +1 more source
MODIFIED RELEASE PHARMACEUTICAL FORMULATIONS COMPRISING DEFERIPRONE
The disclosure is directed to pharmaceutical compositions for oral administration comprising deferiprone. In particular, the disclosure is also directed to modified release tablets suitable either for twice daily administration or once daily ...
Andrea Gazzaniga +3 more
core
Annals of the New York Academy of Sciences, 2010 Deferiprone (DFP) has been evaluated in a wide range of disorders, but most data come from transfusion‐dependent thalassemia. The safety and tolerability profile includes gastrointestinal complaints, liver enzymes elevation, weight gain, arthropathy, neutropenia, and agranulocytosis.
PIGA, Antonio Giulio +5 more
core +5 more sources
Pilot Safety Trial of Deferiprone in 10 Subjects With Superficial Siderosis
Stroke, 2012 Background and Purpose— Superficial siderosis is a neurodegenerative disease caused by toxic accumulation of hemosiderin on the surface of the brain and spinal cord for which there is no known effective treatment.
Michael Levy, Rafael H Llinas
exaly +2 more sources
Deferiprone for the treatment of Friedreich's ataxia
Journal of Neurochemistry, 2013 Friedreich's ataxia (FRDA) is a neurological disease related to a deficiency of the protein frataxin involved in iron-sulfur (Fe-S) cluster biogenesis.
Massimo Pandolfo
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches: